Rivaroxaban is under clinical development by Bio-Synectics and currently in Phase I for Deep Vein Thrombosis (DVT). According to GlobalData, Phase I drugs for Deep Vein Thrombosis (DVT) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rivaroxaban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rivaroxaban overview
Rivaroxaban is under development for the treatment of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism and venous thromboembolism. The drug candidate is an incrementally modified drug. It is administered orally in the form of a tablet. The drug candidate is developed based on NUFS (Nanoparticulation Using Fat and Supercritical fluids) technology. The drug candidate acts by targeting factor Xa.
Bio-Synectics overview
Bio-Synectics is is engaged in the business of nanopharmaceuticals, materials, and drug delivery systems to pharmaceutical industries that specializes in the technology of nanoparticles. It is headquartered in Seoul, Republic of Korea (South Korea).
For a complete picture of Rivaroxaban’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
